Developer docs
API playgroundTry for free, no card

Search company profiles

Rottendorf Pharma

Full company profile

uuid000nxpu

Namestring
Rottendorf Pharma
Legal namestring
Rottendorf Pharma GmbH
Websiteurl
rottendorf.com
Company typeenum
Private
Founded yearint
1928
Descriptiontext

Rottendorf Pharma GmbH is a German contract development and manufacturing organization (CDMO) specializing exclusively in oral solid dosage forms. Founded in 1928 by Andreas J. Rottendorf and rebuilt in Ennigerloh after World War II, the company has spent 95+ years focused on formulation development, commercial bulk manufacturing, packaging (blister, cans, bottles), and analytical services for tablets and mini-tablets. It is 100% owned by the Rottendorf-Stiftung (Rottendorf Foundation), a structure established in 1971 that prevents the company from ever competing with its customers on product. The company is headquartered in Ennigerloh with a wholly-owned US sales subsidiary (Rottendorf Pharma Inc., relocated to Boston, MA in 2025), and a second production campus under construction in Oelde (operations planned for 2028) that will double long-term production capacity. Rottendorf holds full GMP compliance with extensive inspection histories from EMA, FDA, ANVISA and other authorities, is ISO 50001-certified since 2015, and is a member of the UN Global Compact.

The company generates revenue exclusively through B2B contract services for international pharmaceutical companies, operating as a custom-quoted professional services provider with no own-product portfolio. Its four core service lines — Development, Manufacturing, Packaging, and Analytics — are wrapped in three proprietary service concepts: Total Process Ownership (TPO©), Total Technology Mastering (TTM), and Total Supply Integrity (TSI). The company attends major industry events (CPHI Worldwide, FIP, AAPS PharmSci 360, Bio Europe) and sells primarily through direct enterprise engagement with no public pricing or productized offering. Recent strategic actions include a 2026 partnership with Corealis Pharma for integrated early- to late-stage OSD development, the installation of new Gerteis dry granulation roller compactors in 2026, and the Oelde campus expansion. Awards include the CDMO Leadership Award Europe 2025 (Small Molecule Dosage Form, International) and Top Employer Germany 2025.

Rottendorf competes in the oral solid dose segment of the pharmaceutical CDMO market against larger multi-site players, with scale (501–1,000 employees), a single primary manufacturing footprint, and a foundation-owned capital base that supports long-horizon reinvestment rather than short-term shareholder returns. Its competitive position rests on regulatory track record, specialized OSD expertise, and the structural assurance that it will never commercialize competing products.

Short descriptiontext

Rottendorf Pharma is a German CDMO founded in 1928, specializing exclusively in oral solid dosage form development, manufacturing, packaging, and analytics for international pharmaceutical companies. It is wholly owned by the Rottendorf Foundation and operates from Ennigerloh with US presence in Boston.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersEnnigerloh, Germany
HQ citystring
Ennigerloh
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, oral solid dosage forms, pharmaceutical development services, GMP contract manufacturing, tablet manufacturing services
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Rottendorf Pharma operates exclusively as a CDMO, providing development, manufacturing, and packaging services for oral solid dosage forms to pharmaceutical companies. They do not market their own products and therefore never compete with their customers.

rottendorf.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Rottendorf Pharma is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for oral solid dosage forms (tablets and mini-tablets) to international pharmaceutical companies. The service portfolio spans formulation and analytical development, commercial bulk manufacturing, packaging (blister, cans, bottles), and quality analytics, delivered under proprietary service concepts TPO©, TTM, and TSI. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • CDMO Leadership Award Europe 2025 - Small Molecule Dosage Form, International (based on customer satisfaction surveys)
+1 more record
Product overview1 text field

Rottendorf Pharma operates as a Contract Development and Manufacturing Organization (CDMO) specializing exclusively in oral solid dosage forms. The company offers an integrated service portfolio comprising four core capabilities: Development Services (formulation and analytical process development), Manufacturing Services (commercial bulk manufacturing), Packaging Services (blister, cans, bottles), and Analytics Services (quality testing). These core services are enhanced by three proprietary service concepts—Total Process Ownership (TPO©), Total Technology Mastering (TTM), and Total Supply Integrity (TSI)—which together provide comprehensive end-to-end support from early development through commercial supply. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Product and service4 records
1Development Services
CategoryContract Development
Description

Formulation and analytical process development for oral solid dosage forms, spanning pre-formulation through commercial supply, for pharmaceutical company clients seeking integrated OSD development support.

2Manufacturing Services
CategoryContract Manufacturing
Description

Commercial bulk manufacturing of oral solid dosage forms including tablets, covering granulation, mixing, tableting, coating, and dragée production for pharmaceutical company clients under GMP.

3Packaging Services
CategoryContract Packaging
Description

Primary packaging of oral solid dosage forms into blisters, cans, and bottles for pharmaceutical company clients.

4Analytics Services
CategoryContract Laboratory / Quality Analytics
Description

Quality analytics and analytical testing services for oral solid dosage forms, including chemical and physical analyses supporting development, manufacturing, and release for pharmaceutical company clients.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-11
Description

Strategic partnership providing integrated early- to late-stage oral solid dosage (OSD) development services from pre-formulation through commercial supply. Combines Rottendorf's manufacturing and packaging expertise with Corealis's development capabilities for seamless OSD development and manufacturing.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rottendorf Pharma

Pharmaceutical Contract Manufacturing (CDMO)rottendorf.com

Rottendorf Pharma is a German CDMO founded in 1928, specializing exclusively in oral solid dosage form development, manufacturing, packaging, and analytics for international pharmaceutical companies. It is wholly owned by the Rottendorf Foundation and operates from Ennigerloh with US presence in Boston.

What Rottendorf Pharma does

Rottendorf Pharma GmbH is a German contract development and manufacturing organization (CDMO) specializing exclusively in oral solid dosage forms. Founded in 1928 by Andreas J. Rottendorf and rebuilt in Ennigerloh after World War II, the company has spent 95+ years focused on formulation development, commercial bulk manufacturing, packaging (blister, cans, bottles), and analytical services for tablets and mini-tablets. It is 100% owned by the Rottendorf-Stiftung (Rottendorf Foundation), a structure established in 1971 that prevents the company from ever competing with its customers on product. The company is headquartered in Ennigerloh with a wholly-owned US sales subsidiary (Rottendorf Pharma Inc., relocated to Boston, MA in 2025), and a second production campus under construction in Oelde (operations planned for 2028) that will double long-term production capacity. Rottendorf holds full GMP compliance with extensive inspection histories from EMA, FDA, ANVISA and other authorities, is ISO 50001-certified since 2015, and is a member of the UN Global Compact.

The company generates revenue exclusively through B2B contract services for international pharmaceutical companies, operating as a custom-quoted professional services provider with no own-product portfolio. Its four core service lines — Development, Manufacturing, Packaging, and Analytics — are wrapped in three proprietary service concepts: Total Process Ownership (TPO©), Total Technology Mastering (TTM), and Total Supply Integrity (TSI). The company attends major industry events (CPHI Worldwide, FIP, AAPS PharmSci 360, Bio Europe) and sells primarily through direct enterprise engagement with no public pricing or productized offering. Recent strategic actions include a 2026 partnership with Corealis Pharma for integrated early- to late-stage OSD development, the installation of new Gerteis dry granulation roller compactors in 2026, and the Oelde campus expansion. Awards include the CDMO Leadership Award Europe 2025 (Small Molecule Dosage Form, International) and Top Employer Germany 2025.

Rottendorf competes in the oral solid dose segment of the pharmaceutical CDMO market against larger multi-site players, with scale (501–1,000 employees), a single primary manufacturing footprint, and a foundation-owned capital base that supports long-horizon reinvestment rather than short-term shareholder returns. Its competitive position rests on regulatory track record, specialized OSD expertise, and the structural assurance that it will never commercialize competing products.

Rottendorf Pharma firmographics

Firmographics
Name
Rottendorf Pharma
Legal name
Rottendorf Pharma GmbH
Website
https://rottendorf.com
Company type
Private
Founded year
1928
Operating status
Operating
Headcount range
251–500 employees
Short description
Rottendorf Pharma is a German CDMO founded in 1928, specializing exclusively in oral solid dosage form development, manufacturing, packaging, and analytics for international pharmaceutical companies. It is wholly owned by the Rottendorf Foundation and operates from Ennigerloh with US presence in Boston.
Ownership category
akta.pro rank

Rottendorf Pharma industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Oral solid dosage forms
  • Pharmaceutical development services
  • GMP contract manufacturing
  • Tablet manufacturing services

Where Rottendorf Pharma is headquartered

Location

Headquarters

HQ city
Ennigerloh
HQ country
Germany
HQ region
Europe

Offices3 records

Markets served

Rottendorf Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Rottendorf Pharma operates exclusively as a CDMO, providing development, manufacturing, and packaging services for oral solid dosage forms to pharmaceutical companies. They do not market their own products and therefore never compete with their customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Rottendorf Pharma product offering

Product offering

Core offering

Rottendorf Pharma is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for oral solid dosage forms (tablets and mini-tablets) to international pharmaceutical companies. The service portfolio spans formulation and analytical development, commercial bulk manufacturing, packaging (blister, cans, bottles), and quality analytics, delivered under proprietary service concepts TPO©, TTM, and TSI. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Product overview

Rottendorf Pharma operates as a Contract Development and Manufacturing Organization (CDMO) specializing exclusively in oral solid dosage forms. The company offers an integrated service portfolio comprising four core capabilities: Development Services (formulation and analytical process development), Manufacturing Services (commercial bulk manufacturing), Packaging Services (blister, cans, bottles), and Analytics Services (quality testing). These core services are enhanced by three proprietary service concepts—Total Process Ownership (TPO©), Total Technology Mastering (TTM), and Total Supply Integrity (TSI)—which together provide comprehensive end-to-end support from early development through commercial supply. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Development Services Formulation and analytical process development for oral solid dosage forms, spanning pre-formulation through commercial supply, for pharmaceutical company clients seeking integrated OSD development support.
  • Manufacturing Services Commercial bulk manufacturing of oral solid dosage forms including tablets, covering granulation, mixing, tableting, coating, and dragée production for pharmaceutical company clients under GMP.
  • Packaging Services Primary packaging of oral solid dosage forms into blisters, cans, and bottles for pharmaceutical company clients.
  • Analytics Services Quality analytics and analytical testing services for oral solid dosage forms, including chemical and physical analyses supporting development, manufacturing, and release for pharmaceutical company clients.

Quantifiable outcome

  • CDMO Leadership Award Europe 2025 - Small Molecule Dosage Form, International (based on customer satisfaction surveys)
  • +1 more outcomes

Companies that use Rottendorf Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Rottendorf Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Rottendorf Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Corealis PharmacoreStrategic or Co-development Partner · 11 February 2026Strategic partnership providing integrated early- to late-stage oral solid dosage (OSD) development services from pre-formulation through commercial supply. Combines Rottendorf's manufacturing and packaging expertise with Corealis's development capabilities for seamless OSD development and manufacturing.

Scale indicators6 records

Recent moves10 records

Expansion highlights4 records

Rottendorf Pharma competitors and assessment

Company assessment

Market position

Strengths1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Rottendorf Pharma social profiles

Digital presence

Rottendorf Pharma compliance and trust

Trust signal

Compliance6 records

Rottendorf Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rottendorf Pharma leadership team

Management profile

Number of profiles

Profiles12 records

Rottendorf Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Rottendorf Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rottendorf Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rottendorf Pharma

What does Rottendorf Pharma do?

Rottendorf Pharma is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for oral solid dosage forms (tablets and mini-tablets) to international pharmaceutical companies. The service portfolio spans formulation and analytical development, commercial bulk manufacturing, packaging (blister, cans, bottles), and quality analytics, delivered under proprietary service concepts TPO©, TTM, and TSI. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Is Rottendorf Pharma a public or private company?

Rottendorf Pharma is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Rottendorf Pharma founded?

Rottendorf Pharma was founded in 1928. It employs 251 to 500 people.

Where is Rottendorf Pharma based?

Rottendorf Pharma is headquartered in Ennigerloh, Germany, in the Europe region.

How does Rottendorf Pharma make money?

One revenue line is on record: contract Development and Manufacturing (CDMO) Services.

Does Rottendorf Pharma have an API?

No public API is recorded for Rottendorf Pharma.

What industry is Rottendorf Pharma in?

Rottendorf Pharma's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAJ, Packaging, Labeling & Serialization (Clinical/Commercial) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales